| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 995.3 | 1041.3 | 974.4 |
| Other income | 36.0 | 32.1 | 40.7 |
| Total income | 1031.2 | 1073.4 | 1015.0 |
| Profit before exceptional items & tax | 373.1 | 381.9 | 358.6 |
| Exceptional items | 0.0 | 18.0 | 0.0 |
| Profit before tax | 373.1 | 399.9 | 358.6 |
| Net profit | 277.9 | 295.6 | 262.9 |
| Operating margin | 36.2% | 37.3% | 35.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +5.70% |
|---|---|
| Net profit, quarter on quarter | -6.00% |
| Revenue, year on year | +2.10% |
BSE results filing, NSE: GLAXO. Figures extracted from the filing.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,815.70
- Market cap
- ₹47,700 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 44.7×Sector 50.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Earnings Call Transcript: Key Takeaways
GSK India delivered resilient FY26 results with double-digit EBITDA and PAT growth, despite muted 2% revenue growth due to significant supply disruptions from a CMO fire and vaccine shipment delays.
- Call
- Guides 10% growth
GlaxoSmithKline Pharmaceuticals Earnings Call Transcript: Key Takeaways
GSK reported muted 2% revenue growth due to supply chain disruptions at a key CMO, but delivered record-high EBITDA margins of 35% through cost optimization and a shift toward high-margin specialty products.
- Call
- Guides 10% growth
GlaxoSmithKline Pharmaceuticals Investor Presentation: Key Takeaways
GSK India delivered strong Q1 FY27 standalone performance with revenue growing 15% and PAT up 24%, driven by portfolio transformation and core brand leadership.
GlaxoSmithKline Pharmaceuticals Q1 FY27 Results: Net Profit ₹237.2 Cr, Up 15.7% YoY
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹938.4 Cr (+16.5% YoY) and net profit of ₹237.2 Cr (+15.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹237.2 Cr · +15.7% YoY
GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways
GSK Pharma Q4 FY26 earnings call highlighting 2% revenue growth, 34% EBITDA margins, and a shift toward an innovation-led specialty portfolio.